道通科技(688208.SH):達晨創泰等4名股東累計減持440.01萬股 合計持股減至5%以下
格隆匯12月20日丨道通科技(688208.SH)公佈,達晨創泰、達晨創恆、達晨創瑞及達晨創豐於2021年4月2日-2021年12月16日通過大宗交易方式減持公司無限售流通股數量合計440.01萬股,佔公司總股本的0.9778%。
本次權益變動後,達晨創泰、達晨創恆、達晨創瑞、達晨創豐合計持有公司股份數從26,900,000股減少至22,499,900股,佔公司總股本比例從5.9778%減少至4.99998%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.